ATE76747T1 - Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. - Google Patents

Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Info

Publication number
ATE76747T1
ATE76747T1 AT87107979T AT87107979T ATE76747T1 AT E76747 T1 ATE76747 T1 AT E76747T1 AT 87107979 T AT87107979 T AT 87107979T AT 87107979 T AT87107979 T AT 87107979T AT E76747 T1 ATE76747 T1 AT E76747T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
methyl ester
preparation
compositions containing
therapeutic uses
Prior art date
Application number
AT87107979T
Other languages
English (en)
Inventor
Paolo Chiesi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT20737/86A external-priority patent/IT1190342B/it
Priority claimed from IT19221/87A external-priority patent/IT1203321B/it
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE76747T1 publication Critical patent/ATE76747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87107979T 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. ATE76747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT20737/86A IT1190342B (it) 1986-06-10 1986-06-10 Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche
IT19221/87A IT1203321B (it) 1987-01-30 1987-01-30 Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche
EP87107979A EP0252290B1 (de) 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische Zusammensetzungen, ihre Herstellung und therapeutische Verwendungen

Publications (1)

Publication Number Publication Date
ATE76747T1 true ATE76747T1 (de) 1992-06-15

Family

ID=26327098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87107979T ATE76747T1 (de) 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Country Status (13)

Country Link
US (2) US4826875A (de)
EP (1) EP0252290B1 (de)
JP (1) JP2572768B2 (de)
KR (2) KR880000092A (de)
AT (1) ATE76747T1 (de)
AU (1) AU605154B2 (de)
CA (1) CA1303509C (de)
DE (2) DE3779500T2 (de)
ES (1) ES2042520T3 (de)
GR (1) GR880300058T1 (de)
HU (1) HUT43952A (de)
NZ (1) NZ220631A (de)
PT (1) PT85055B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
DE4325435A1 (de) * 1993-07-29 1995-02-02 Basf Ag Neue Wirkstoffkombination
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
AU702161B2 (en) * 1995-03-02 1999-02-18 R.P. Scherer Limited Pharmaceutical compositions comprising monoamine oxidase B inhibitors
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
NZ309980A (en) 1995-06-07 2001-06-29 Noven Pharma Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature
CA2236368C (en) * 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
IL130528A (en) 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
BR9908713A (pt) * 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
AU764844B2 (en) 1998-11-10 2003-09-04 Teva Pharmaceutical Industries Ltd. Process for manufacture of L-DOPA ethyl ester
CA2350304A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing l-dopa ethyl ester
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
AU2001296703A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1622450A4 (de) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions Verfahren zur förderung des durchschlafens durch verabreichung von trospiumchlorid
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
NZ546662A (en) * 2003-10-20 2009-03-31 Teva Pharma Composition and dosage form for sustained effect of levodopa
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
DK1751087T3 (da) * 2004-06-04 2012-07-16 Xenoport Inc Levodopa-derivater og sammensætninger og anvendelser deraf
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
DK1959948T3 (da) 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
CN103142570A (zh) * 2005-12-09 2013-06-12 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil 用于神经保护的用途
DK1991522T3 (en) * 2006-02-17 2016-08-29 Imphar Ag Deuterated CATECHOLAMINDERIVATER AND medicaments comprising THESE RELATIONS
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
EP2125702A1 (de) 2006-12-21 2009-12-02 Xenoport, Inc. Levodopadimethylsubstituierte diester-prodrugs, zusammensetzungen und verwendungsverfahren
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
KR20150046328A (ko) 2007-02-06 2015-04-29 네우로퀘스트 아이엔씨. 신경 전달을 억제하기 위한 테르펜 화합물을 포함하는 조성물 및 방법
WO2009032202A1 (en) * 2007-08-29 2009-03-12 Nuon Therapeutics, Inc. Treatment of brain disorders
CN101283965B (zh) * 2007-10-26 2010-06-16 南京长澳医药科技有限公司 一种含左旋多巴甲酯的制剂及制备方法
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9415023B2 (en) 2008-08-13 2016-08-16 Neuroquest Inc. Compositions comprising terpene compounds for treating negative sensory phenomena
CA2740017A1 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US8286311B2 (en) 2008-10-31 2012-10-16 Jisook Paik Buckle
US20120128654A1 (en) * 2009-04-23 2012-05-24 University Of Cincinnati Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma
MX2011012315A (es) 2009-05-19 2011-12-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
KR101196354B1 (ko) 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
EP3326615B1 (de) 2010-11-15 2020-01-08 Neuroderm Ltd Kontinuierliche verabreichung von l-dopa, dopa-decarboxylase-inhibitoren, catechol-o-methyl-transferase-inhibitoren und zusammensetzungen dafür
CA2823642A1 (en) * 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
EP3456315A1 (de) 2012-06-05 2019-03-20 Neuroderm Ltd Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon
US10188617B2 (en) 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy
JP6442475B2 (ja) 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
US9751869B2 (en) 2013-03-15 2017-09-05 Bristol-Myers Squibb Company LXR modulators
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
WO2015054302A1 (en) 2013-10-07 2015-04-16 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
EP3758754A1 (de) 2018-03-02 2021-01-06 Chiesi Farmaceutici S.p.A. Pharmazeutische formulierung zur intraduodenalen verabreichung mit melevodopa und carbidopa
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4267113A4 (de) 2020-12-22 2025-02-12 Amneal Pharmaceuticals LLC Levodopa-dosierschema
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease
WO2025075499A1 (en) 2023-10-02 2025-04-10 Universiteit Van Amsterdam Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787581A (en) * 1970-03-24 1974-01-22 M Sandler Pharmaceutical compositions and methods of treatment
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
KR880000092A (ko) 1988-03-23
PT85055A (pt) 1988-07-01
HUT43952A (en) 1988-01-28
JP2572768B2 (ja) 1997-01-16
DE3779500T2 (de) 1993-01-21
CA1303509C (en) 1992-06-16
KR950002150B1 (ko) 1995-03-14
US4826875A (en) 1989-05-02
EP0252290B1 (de) 1992-06-03
JPS6327428A (ja) 1988-02-05
PT85055B (pt) 1994-10-31
ES2042520T3 (es) 1993-12-16
DE252290T1 (de) 1988-06-09
EP0252290A3 (en) 1990-01-24
KR890001533A (ko) 1989-03-27
US5017607A (en) 1991-05-21
AU605154B2 (en) 1991-01-10
DE3779500D1 (de) 1992-07-09
EP0252290A2 (de) 1988-01-13
AU7405387A (en) 1987-12-17
NZ220631A (en) 1990-12-21
GR880300058T1 (en) 1988-10-18

Similar Documents

Publication Publication Date Title
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE3686483D1 (de) Arzneimittel.
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
ATE161836T1 (de) 4-substituierte-2-deoxy-2,3-didehydro alpha-d- neuraminsäure antivirale derivate
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
NO904986L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
SE8404065D0 (sv) Novel biologically active compounds
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
NO900697D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
NO167801C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
TH14574A (th) สารผสมทางเภสัชกรรม
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
NO164651C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminofenol-derivater.
NO168106C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av hexahydro-8-hydroxy-2,6-methano-2h-kinolizin-3(4h)-on

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time